Options traders have turned notably bullish on APO — the most striking shift in the data this week.
The put/call ratio dropped to 0.81 on Tuesday, more than 3.5 standard deviations below its 20-day average of 0.90. That's an extreme call-side skew. At 0.81, the PCR sits near the lower end of its 52-week range of 0.55–1.00, pointing to a meaningful rotation toward upside exposure heading into Apollo's next earnings event on June 8. The move comes even as the stock slipped 2.2% on Tuesday to close at $131.15 — a divergence worth watching, where equity price and options sentiment are pulling in opposite directions.
Short positioning tells a more measured story. Short interest climbed modestly to 5.6% of free float — up about 2% on the week and 6.5% over the past month, a slow drift rather than an aggressive build. Borrow conditions offer no sign of crowding. The cost to borrow is a low 0.49%, and availability is a comfortable 249% of short interest, meaning there are roughly 2.5 shares available to lend for every one currently borrowed. That's well within normal range and has actually loosened from around 211% last week. There is no borrow squeeze dynamic here.
The Street has been busy repositioning around Apollo's recent Q1 results. Most of the post-earnings analyst moves were constructive: UBS raised its target to $158 and maintained Buy; RBC and Barclays both lifted targets, with Barclays moving to $131. The notable outlier this week was TD Cowen, which trimmed its target from $155 to $146 while staying at Buy — a modest downward revision that reflects caution on near-term estimates without abandoning the bull case. The consensus mean target at $149.65 represents roughly 14% upside from Tuesday's close. The bull case centres on record Retirement Services inflows of $17.2 billion and a strong deployment pipeline; the bear case points to softening SRE growth expectations and competitive headwinds in the retail channel. Apollo's forward EPS growth profile remains the standout factor — the 12-month forward EPS year-on-year increase ranks in the 87th percentile across the universe, even as near-term EPS momentum scores look more pedestrian.
On the ownership side, Capital Research added nearly 10 million shares through April, making it the largest institutional holder at 9.6% of shares outstanding. By contrast, CEO Marc Rowan sold 140,000 shares earlier this month — a relatively small transaction in the context of his near-5% stake. The CFO made a routine sale of 7,000 shares in mid-May at $134.65. Overall insider activity in the past 90 days has netted to selling of roughly $8 million in value, with no purchases on record. That's not an alarming pattern for a financial firm where executives hold large stakes and sell on schedule, but there are no insider buys to counter the drift.
Among correlated peers, the picture reinforces the sector-wide softness on Tuesday. CRBG fell 3.1% on the day and EQH dropped 3.6%, both outpacing Apollo's decline — suggesting the Tuesday move was sector-driven rather than APO-specific. On the week, CRBG and EQH remain up 2.3% and 1.6% respectively, while Apollo is flat with a 0.6% weekly loss, meaning Tuesday's drop came after relative strength earlier in the week.
The June 8 earnings date is the focal point now. After the Q1 print produced a 1.9% one-day decline before recovering over the following week, the question heading into Q2 is whether the Retirement Services momentum holds and whether the company can demonstrate that SRE growth is stabilising above the mid-single-digit pace the bears have priced in.
See the live data behind this article on ORTEX.
Open APO on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
